Recombinant Human Heat-Stable Enterotoxin Receptor (GUCY2C) Protein (His)

Name: Recombinant Human Heat-Stable Enterotoxin Receptor (GUCY2C) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03918P
Price: 240.0 USD
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, Back to school. back to lab. ready for results. - advance your research with beta lifescience, High-quality recombinant proteins, In-stock recombinant proteins, Other recombinant proteins

Price Save $1,164

Size

100ug

Quantity

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Heat-Stable Enterotoxin Receptor (GUCY2C) Protein (His) is produced by our Baculovirus expression system. This is a extracellular protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P25092
Target Symbol	GUCY2C
Synonyms	GC-C; Guanylyl cyclase C; GUC2C; GUC2C_HUMAN; GUCY2C; Heat stable enterotoxin receptor; Heat-stable enterotoxin receptor; hSTAR; Intestinal guanylate cyclase; STA receptor
Species	Homo sapiens (Human)
Expression System	Baculovirus
Tag	N-10His
Target Protein Sequence	SQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEIVRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYSTFQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVYKNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKLKGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALAYLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTKKYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGPQ
Expression Range	24-430aa
Protein Length	Extracellular Domain
Mol. Weight	48.5 kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Receptor for the E.coli heat-stable enterotoxin (E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GC-C). Also activated by the endogenous peptides guanylin and uroguanylin.
Subcellular Location	Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Note=The 145 kDa plasma membrane form of GC-C contains sialic acid and galactose residues, while a differencially glycosylated 130 Kda form is a high mannose form that is resident in the endoplasmic reticulum and may serve as the precursor for the cell surface form.
Protein Families	Adenylyl cyclase class-4/guanylyl cyclase family
Database References	HGNC: 4688 OMIM: 601330 KEGG: hsa:2984 STRING: 9606.ENSP00000261170 UniGene: PMID: 28418917 The findings support that the activating mutation in GUCY2C creates an intestinal environment with a major influence on the microbiota, which could contribute to the increased susceptibility to inflammatory bowel disease in patients with Familial GUCY2C diarrhea syndrome. PMID: 28902124 the expression of GCC is maintained throughout the process of tumor progression and formation of metastatic disease. PMID: 29261789 To investigate gut motility and hormones before and after a meal in Familial GUCY2C diarrhea syndrome patients and compare with healthy controls PMID: 28957388 Mutations in GUCY2C indicate a role for this receptor in the pathogenesis of sporadic Congenital secretory diarrhea. PMID: 25994218 these data support Ad5-GUCY2C-PADRE as a safe and effective vaccination strategy in preclinical models and position Ad5-GUCY2C-PADRE for Phase I clinical testing in colorectal cancer patients. PMID: 27903079 Familial GUCY2C diarrhoea syndrome is caused by an activating mutation in the GUCY2C gene, which causes impaired contractility and fluid stagnation in the small bowel PMID: 27338166 Findings show how caloric suppression of the guanylin-GUCY2C signaling axis links obesity to negation of a universal tumor suppressor pathway in colorectal cancer. PMID: 26773096 Data show that individuals affected with meconium ileus (MI) had either homozygous or compound heterozygous variants in enterotoxin receptor GUCY2C. PMID: 25370039 High guanylyl cyclase C expression is associated with colon cancer recurrence. PMID: 24919572 Transmission disequilibrium tests (TDT), case-control studies and quantitative analyses indicated association between GUC2C with Attention-deficit/hyperactivitydisorder and its core symptoms. PMID: 25064385 Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21. PMID: 24217248 GUCY2C signaling constitutes a direct link between the initiation of colorectal cancer and the induction of its associated desmoplastic stromal niche. PMID: 24085786 Data show that lower survival (OS) and disease-free survival (DFS) rates were significantly associated with guanylate cyclase C (GCC) and CK20 mRNA levels. PMID: 23150200 Interaction with VIP36 is dependent on glycosylation at the same sites that allow GC-C to fold and bind ligand. PMID: 23269669 GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity PMID: 22384056 Mutations in GUCY2C were associated with the Meconium ileus phenotype. downregulation of GUCY2C leads to a cystic fibrosis-like intestinal phenotype. PMID: 22521417 We identified a heterozygous missense mutation (c.2519G-->T) in GUCY2C in all family members with familial diarrhea syndrome. PMID: 22436048 High guanylyl cyclase C is associated with colon cancer. PMID: 21533822 Data suggest that monitoring the peripheral blood GCC expressions may allow employing different treatment options to metastatic CRC patients. PMID: 21901559 Lymph nodes (range: 2-159) from 291 prospectively enrolled node-negative colorectal cancer patients were analyzed by histopathology and GUCY2C quantitative RT-PCR. PMID: 21307149 Longer survival was associated with hypomethylation at specific CpG sites (e.g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e.g. TMCO5, PTPRN and GUCY2C). PMID: 21577013 A novel PDZ protein regulates the activity of guanylyl cyclase C, the heat-stable enterotoxin receptor. PMID: 11950846 guanylyl cyclase c is ectopically expressed in primary and metastatis adenocarcinoma of the esophagus and stomach PMID: 12163327 SH3 domain -mediated protein-protein interaction with the catalytic domain of guanylyl cyclase C inhibited the cyclase activity and might be pivotal for the desensitization phenomenon of the guanylyl cyclase C receptor PMID: 12649275 gelatinolytic activity of GCC in colorectal tumor tissues may facilitate the hepatic metastatic process in the steps after intravasation but not during or before intravasation PMID: 14581363 a novel role for glycosidic modification of GC-C during its biosynthesis, in imparting subtle conformational changes in the receptor that allow for ligand-mediated activation and perhaps regulation of basal activity PMID: 14748740 Lack of guanylyl cyclase c expression assoeciated with significant reduction in adenomas in Apc(Min/+);Gucy2c(-/-) mice PMID: 15825168 Transformation associated with reflux at the gastroesophageal junction reflects activation by bile acid and acid of a transcriptional program involving NF-kappaB and Cdx2, which mediate intestinal metaplasia and ectopic expression of GC-C. PMID: 16618413 This validated assay is being applied to approximately 10,000 lymph nodes in a prospective trial to define the sensitivity of Guanylyl cyclase C(GCC) qRT-PCR for staging patients with colorectal cancer. PMID: 16899600 docking of the c-src SH2 domain to phosphorylated GC-C results in colocalization and further activation of c-src. PMID: 19620276 the role of the linker region in receptor guanylyl cyclases PMID: 19648115 GCC is a specific marker for differentiating primary and secondary metatstatic ovarian mucinous neoplasms. PMID: 19694825 Results suggest that GUCY2C quantitative reverse transcriptase (qRT)-PCR can be used to detect occult lymph node metastases in pN0 colorectal cancer patients. PMID: 19895223 Expression of the receptor guanylyl cyclase C and its ligands in reproductive tissues of the rat: a potential role for a novel signaling pathway in the epididymis. PMID: 12444076 The protein kinase-like domain in receptor guanylyl cyclase C provides a critical structural link between the extracellular domain and the catalytic domain in regulation of this family of receptors. PMID: 11478887

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human Heat-Stable Enterotoxin Receptor (GUCY2C) Protein (His)

Recombinant Human Heat-Stable Enterotoxin Receptor (GUCY2C) Protein (His)

Product Overview

Target Details

FAQs